Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Comment by fdjens1on Feb 24, 2021 9:53am
88 Views
Post# 32645790

RE:The importance of Share Liquidity With DTCC Full Service

RE:The importance of Share Liquidity With DTCC Full Service Yes to get a DOW or NASDAQ listing this is required.

The news Biov released was an important future step is a requirement of  large U.S. trading exchanges. This is a clue to where management wants to trade. The CEO himself experienced in New York trading has his eye on a bigger prize.

VANCOUVER, British Columbia Feb. 16, 2021 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA:5LB, OTC:LMNGF) ( "BioVaxys" or "Company") is pleased to announce that the company has been approved for DTCC full service eligibility in the United States and its shares are qualified to be held at the Depository Trust Company ("DTC") and traded and serviced through DTC's electronic book-entry system. DTC is a subsidiary of the Depository Trust & Clearing Corp. ("DTCC"), an American company that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States .
<< Previous
Bullboard Posts
Next >>